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ABSTRACT 
 
  Huntington's disease (HD) is one of the most destructive progressive 
neurodegenerative disorders, and is caused by a genetic mutation in the HTT gene 
encoding Huntingtin.  To assist Neil Aronin's ongoing HD research at UMass Medical 
Center, we developed a more efficient protocol for mouse cortical dissection and plating.  
In addition, we optimized a procedure for transducing cortical cells with lentiviruses 
containing various siRNAs and GFP, and assayed the percent knockdown by qRT-PCR.  
In the future, these procedures will help assess the role of previously identified protein 
partners of mutant Huntingtin that contribute to HD pathogenesis. 
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BACKGROUND 
 
 
Millions of people worldwide are afflicted with hundreds of genetic disorders.  A 
genetic disorder is a type of disease that results from a mutation or abnormality in one‟s 
genetic makeup.  These can be caused by a multitude of reasons; some are caused by a 
single mutation in a gene, while others involve many deletions or insertions of various 
sizes (University of Utah, 2011).  Some of the best known genetic diseases are Down 
syndrome, Alzheimer‟s disease, Cystic Fibrosis, and Huntington‟s disease.  
 
Huntington’s Disease Description 
 Huntington‟s disease (HD) is one of the most destructive genetic brain disorders 
(Huntington's Disease Society of America, 2008).  Scientists typically refer to it as a 
„progressive neurodegenerative disorder‟ (Gusella et al., 1983) due to the prevalence of 
genes that are programmed to deteriorate neurons located in various regions of the brain.  
Progressive deterioration leads to severe loss of bodily functions, such as coordinated 
movement, thought and behavioral functions.  The onset of the disease more commonly 
occurs later in an individual‟s life, and is usually detected between the ages of 30 and 50; 
however, rare cases of juvenile HD have been seen in children as young as two 
(Huntington's Disease Society of America, 2008).  Since HD is a genetic condition, the 
mutation is passed through generations (National Institute of Neurological Disorders and 
Stroke, 2010) and is inherited though autosomal dominance (Gusella et al., 1983).  For 
this reason it has a greater risk of affecting the offspring of individuals that have HD.  For 
example, if one parent has HD they have a 50 percent chance of passing it to their 
offspring – causing them to be afflicted with the disease (Figure 1).  Likewise, if that 
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child does not receive the gene for HD, they cannot pass the gene to their children.   As a 
result, if both parents have Huntington‟s, there is a 100 percent chance that their offspring 
will have the gene for the disease.  Upon inheritance, the individual will eventually get 
the disease; it is hard to predict the onset as patients develop symptoms at varying rates 
and severity.  Considering the fact that Huntington‟s is a highly inheritable disease, 97 to 
99 percent of people that have Huntington‟s had a known family member with the disease 
(National Institute of Neurological Disorders and Stroke, 2010).  
 
 
 
 
 
 
 
 
 
 
People Affected by HD 
 Huntington‟s disease affects about 250,000 Americans; whether they have it or 
are at risk of getting it (Huntington's Disease Society of America, 2008).  It is estimated 
that approximately five to ten people out of 100,000 people have HD.  Due to late-onset 
of this disease, this number is not necessarily accurate as most individuals have had 
children before realizing they have HD, unknowingly affecting more of the population 
(Gusella et al., 1983).  HD is not a sex-linked genetic disorder, so it affects both men and 
Figure 1: Example Pedigree Chart of Huntington's Disease.  (Neuroethics, 2011) 
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women equally.  Interestingly, it appears to be more prevalent in people of European 
decent – as opposed to African, Japanese, and Chinese descendants (Genetics Home 
Reference, 2008).  
 
Causes of Huntington’s 
Huntington‟s disease is caused by a genetic mutation in a gene HTT, used to make 
the protein Huntingtin.  Its exact role remains unknown, but it has been shown to play a 
crucial part in brain neurons.  The Huntington‟s disease HTT mutation (mHTT) has a 
specific DNA segment interrupted by a CAG trinucleotide repeat (cytosine, followed by 
an adenine, and then a guanine), which is repeated many times continuously (Figure 2).  
Individuals with normal, wild-type HTT have a CAG sequence that is generally repeated 
between 10-35 times, while people with mHTT have a repeat from 36 to over 120 times. 
 
 
Figure 2: Example of CAG Repeat Sequences in HTT.  Shown are example CAG trinucleotide 
repeat sequences in normal individuals (top row) and HD patients (bottom row) (“What are 
Polyglutamine Diseases?”, 2002) 
 
People who have over 40 CAG repeats almost always have the disease, while 
people that have 36-40 will not necessarily have HD (Genetics Home Reference, 2008).  
 8 
If a person has between 27 and 35 repeats, their children are at risk for HD because as the 
gene is inherited, it has an increased chance of lengthening.    
The increase in CAG repeats results in a much longer Huntingtin protein.  This, 
larger than average, piece of protein is then cut into smaller pieces which become 
detrimental to the body as they join together and collect in the neurons of the brain.  
Aggregation of these fragments causes the neurons in the brain to deteriorate, resulting in 
a loss of crucial elements that control everyday thoughts, movements, and actions 
(Genetics Home Reference, 2008).  The 
further progression of neuronal decay 
increases the severity of the disease, 
eroding the folds and separations found 
in the brains of non-afflicted individuals 
which cause the patients to suffer more 
(Figure 3).  Some people lose up to 25 
percent of their brain with HD 
(University of Utah, 2011).  
 
 
  
Figure 3: Brain Morphology of Huntington's Disease 
(upper) vs. Unaffected (lower).   Folding@Home, 
2010) 
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HD Symptoms 
 There are a variety of different symptoms associated with Huntington‟s disease, 
which can be broken down into the follow categories: juvenile symptoms, early 
symptoms, and late onset symptoms.  Although juvenile and adult Huntington‟s disease 
have the same molecular basis for disease (increased CAG repeats in HTT), there are 
distinct differences in the progression and physiological depiction of the symptoms.  
 
Juvenile Onset 
Some of the first signs of juvenile Huntington‟s are slow movements, frequent 
falls, clumsy, impaired or slurred speech, and drooling.  As the disease progresses, the 
quality of their schoolwork slowly drop because their thinking and logic skills are 
decreasing. Children that have Huntington‟s disease often have seizures; this occurs in 
almost 50 percent of childhood cases (Genetics Home Reference, 2008).   Advancement 
of the disease results in children having increased movement issues, accompanied by 
emotional and mental alterations.  Another key difference is that juvenile HD is generally 
faster progressing, shortening the child‟s lifespan to about 10 years after onset, as 
opposed to the 10-25 years for adults. 
 
Adult Onset 
 As for adult-onset individuals, there are early signs and then symptoms that are 
slower to progress.  The early signs include mostly cognitive and movement issues, 
which can be as simple as becoming clumsy, having mood swings, or experiencing 
depression and memory loss.  As the brain continues to deteriorate these symptoms 
become worse, short and long term memory loss can occur, and uncontrolled movement 
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of the head and other body parts can also be present. The affected person can also start to 
have difficulty walking and talking (Huntington's Disease Society of America, 2008). 
 Through the progression of the disease, these symptoms become worse. 
Individuals become very irritable with forceful and sometimes violent outbursts. They 
eventually have issues making their own decisions and remembering occurrences, while 
their motor skills slowly depreciate.  Loss of motor skills causes a HD patient to fall more 
often, which leads to an increased risk of injury.   As this loss continues, they become 
incapable of swallowing and eating, and are unable to move without assistance.  They 
slowly become dependent on others to take care of them (Huntington's Disease Society of 
America, 2008).  
 
HD Treatments After Diagnosis 
One of the most devastating aspects of Huntington‟s disease is there is no cure.  
Individuals who get HD will die suffering from this disease; however HD is not usually 
the direct cause of death.  Fatality is usually caused by major complications of the 
disease, such as, choking, infections, or heart problems (Huntington's Disease Society of 
America, 2008).   Although there is no way to halt the progression of Huntington‟s 
disease or reverse its effects, medications can help relieve some of the symptoms. These 
medications help control the involuntary muscle movements or to help treat depression.  
In 2008, a new medicine called tetrabenazine (Figure 4) was approved by the U.S Food 
and Drug Administration to help treat Huntington‟s disease (National Institute of 
Neurological Disorders and Stroke, 2010). Since the disease affects mobility, it is crucial 
for people with HD to keep active.  Also, due to its effect on cognitive skills, HD patients 
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should try to keep their minds sharp by doing puzzles, word games, and intellectual 
activities (National Institute of Neurological Disorders and Stroke, 2010). 
 
 
 
 
 
 
 
 
 
 
Current HD Research  
 Although there is currently no cure for HD, extensive research is being done in 
attempts to find one.  While neurobiologists study the fundamental aspects of the disease, 
researchers are also performing animal testing, functional and structural neuroimaging, 
fetal tissue work, and human clinical research (NINDS, 2010).  These approaches aid our 
understanding of HD and may lead to a cure. 
 
Neurobiology 
 Neurobiology, or the study of neurons, is one of the most fundamental forms of 
HD.  Considering HD‟s deteriorating effects on the brain, neurobiology plays a crucial 
role in finding a cure and is a major component in ongoing research. Since the discovery 
of the HTT Huntingtin gene, neurobiologists have been trying to understand how it 
Figure 4: Chemical Structure of Tetrabenazine for 
Treating HD Patients.  (Chemical Register, 2011) 
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contributes to HD pathogenicity (NINDS, 2010).  Through previous investigations, 
specific parts of the brain have been labeled and their functions identified.  For example, 
the basal ganglion area has been shown to help control movements.  Knowing this type of 
information coupled with which areas of the brain are affected by HD will help make 
correlations to symptoms (Tan, 2001). 
 
Clinical Research 
 Various professionals, including neurologists and psychiatrists, are working 
together with patients to control symptoms.  For instance, clinical trials are currently 
being performed to study the effects of various medications including tetrabenazine on 
symptoms (NINDS, 2010).  One way to help track the effects of various drugs is through 
neuroimaging. 
 
Neuroimaging 
 Neuroimaging provides a significant source for data in HD research, allowing 
researchers to visualize what is going on in a patient‟s brain. One of the major types of 
imaging is called positron emission tomography (PET).  PET is performed following the 
administration of a radioactive substrate (such as glucose) to yield a three dimensional, 
colored image of functional processes within the human body (Nordqvist, 2009).  
Performing routine PET scans on HD patients allows researchers to see the structures in 
the brain to determine how they change throughout the disease‟s progression, or to 
monitor potential improvements following therapies (NINDS, 2010).  
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Animal Testing 
 Following the identification of the HD gene (HTT), its effects on the brain are 
becoming clearer through animal experiments.  For example, transgenic mice have been 
created that mimic the extensive HTT trinucleotide repeats.   Researchers use such mice 
to perform tests and to test drugs to study the progression of the disease (NINDS, 2010).  
 
Fetal Tissue 
 Most HD fetal tissue research is performed using rodents and small, non-human 
primates.  Researchers graft fetal tissue into animals to test whether it can replace 
damaged areas and reverse the neuron loss caused by HD (NINDS, 2010).  Fetal brains 
are also being analyzed to investigate the earliest stages of the disease.  Early analysis 
may reveal aspects about HD that other research cannot. 
 
University of Massachusetts Medical Center’s HD Research 
 The University of Massachusetts Medical Center (UMass) is performing research 
which incorporates several aspects of the aforementioned methods.  The goal is to 
“catalyze our world-class basic research into scientific discoveries with high impact 
clinical applications and overcome the barriers in translating knowledge into clinical 
practice” (UMass Medical School, 2011).  In pursuing this, they have become an 
internationally acknowledged research institution, with several award winning and life 
changing discoveries, including the Nobel Prize work on RNA interference (RNAi) by 
Craig Mello, PhD.   
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 RNAi is a pathway that cells use to silence gene activity.  By understanding this 
process, researchers can manipulate specific gene activity to study the effects of 
decreasing the expression of a specific gene.  Knocking down a gene‟s activity aids in 
identifying that gene‟s significance to the development and maintenance of life.  In order 
to do so, synthesized dsRNA (or the gene encoding it) containing a sequence 
complementary to the gene to be knocked down is introduced inside a cell using 
microinjection or viral delivery.  This dsRNA will be recognized as exogenous genetic 
material and will activate the RNAi pathway, leading to the degradation of the mRNA for 
that specific gene.   RNAi is being used to investigate treatments for HIV and HD, and 
other disorders (NIGMS, 2011).  Neil Aronin, MD and professor of medicine, cell 
biology, and physiology at UMass, has incorporated RNAi technology into his ongoing 
HD research (see below). 
 
Dr. Aronin’s Research 
 Over the last few decades, Dr. Aronin has been an influential role in the 
advancement of both the understanding and development of potential treatments and 
cures for HD.  He has collaborated internationally and his work has appeared in highly 
reputable journals including Science, Journal of Neurophysiology, Journal of 
Neuroscience, Proceedings of the National Academy of Sciences, and Cell Press.  To 
briefly outline his influential career: 
 In 1995, he contributed to proving that there is a correlation between the presence 
of additional glutamine residues and the size of mutant huntingtin, as well as 
providing evidence that the translation of multiple mutant huntingtin protein 
products results from somatic heterogeneity (Aronin et al., 1995).  These results 
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led to studies that determine the origin of the mutant huntintin proteins and their 
potential contribution to pathological and functional changes in HD. 
 In 1997, Dr. Aronin assisted in an experiment that showed that regions in the 
brain afflicted with HD accumulate and aggregate mHTT in the neuronal 
intranuclear inclusions and dystrophic neurites.  Based on these findings, 
researchers proposed that neuronal dysfunction could result from huntingtin 
aggregation (DiFiglia et al., 1997) 
 In 2000, Dr. Aronin worked with a team who studied the HD neuropathology.  
Their findings showed that autophagy and membrane tubulation of the 
endosomal--lysosomal system is induced by cytoplasmic aggregation of mHTT.  
This is important because they also showed that the endosomal--lysosomal system 
is the main pathway for removing excess huntingtin (Kegel et al., 2000). 
 In 2007, Dr. Aronin silenced mHTT in transgenic HD mice using siRNA, showing 
that RNAi may be a promising therapy for HD.  Tranducing cc-siRNA-HTT 
effectively reduced mHTT protein, and blocked both neuropathology and motor 
deficits (DiFiglia et al., 2007). 
 
Dr. Aronin’s Current Research 
Currently, Dr. Aronin and his lab are developing siRNA therapies to silence only 
mHTT mRNA, while increasing the efficiency and durability of the treatment. 
Specifically, they are trying to identify the role of previously verified protein partners of 
mHTT that contribute to HD pathogenesis by knocking down expression of the potential 
partner.   Various siRNAs delivered by lentiviral vectors are being tested on embryonic 
mouse cortical neurons (Figure 5).  Positives identified by the primary culture screen will 
then be used to treat transgenic HD mice using adeno-associated viruses. 
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Figure 5: Diagram of a Lentivirus Vector Encoding an shRNA to Knockdown 
Expression of a Specific Gene of Interest (Aronin, 2010). 
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PROJECT PURPOSE 
 
To assist Dr. Aronin and his team with their goal of using siRNAs to knock down 
expression of candidate genes that may interact with mHTT protein, the goal of this 
project is to optimize procedures for more efficiently deriving mouse embryonic cortical 
cultures, including tissue dissection, plating, and maintenance.  In addition, the project 
will help optimize procedures for treating the primary cultures with lentiviruses encoding 
various siRNAs (and GFP), by assaying the percent knockdown as a measure of 
effectiveness.  RNA will be isolated from transduced cells, then qRT-PCR will be used to 
assay percent knockdown.  The development of these procedures will aid the Aronin 
lab‟s goal of verifying the role of previously identified protein partners of mHTT protein 
in HD pathogenesis. 
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METHODS 
 
Materials 
 
Materials (Supplier) Components Usage 
DMEM/F12 (Gibco)  L-Glutamine 
 2.438 g/L Sodium 
Bicarbonate 
Media used for fetal mice and 
brain removal “pouring media” 
∆ FBS  Added to NB4 Active to make 
“plating media” 
5‟FdU  Antimitotic added to “feeding 
media” 
HypernateE (BrainBits)  Phenol Red Media used for brain dissection 
and storage during dissection 
NB4 Active (BrainBits)  Neurobasal 
 B27 
 Dipeptide L-Alanyl-L-
Glutamine 
 Creatine 
 Estrogen 
 Cholesterol 
Media used for both “plating 
media” and “feeding media” 
Papain (Worthington 
Biochemical 
Corporation) 
 Protease used for cell 
dissociation 
Poly-L-Lysine P4707 
(Sigma) 
 Residue used to coat 6 well 
plates 
TripLE Express (Gibco)  Phenol Red Protease used for cell 
dissociation 
5‟ UtP  Antimitotic added to “feeding 
media” 
 
 
Dissection Protocol 
  The first and most fundamental part of the project was to develop a more efficient 
mouse cortical dissection and plating protocol.  Throughout the project, many changes 
were made in the original procedure to improve efficiency and viability. The dissection 
protocol can be divided into set-up, which remained fairly constant in this project, and 
fetal mouse brain dissection, which changed significantly in this project. 
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 Prior to dissection, two sterile areas were prepared for pup and brain removal, 
respectively.  Both areas were covered by a sterile pad and equipped with sterilized 
forceps and scissors.  The area for pup removal, from the uterus, had a beaker of 
approximately 300 mL of 70% ethanol for sterilizing the pregnant mouse, a beaker of 
approximately 50 mL of pouring medium to rinse the uterus after removal, and a large 
culture dish containing 20 mL of pouring medium for the uterus.  On the dissecting bench 
were three small culture dishes, one containing 1 mL of HypernateE (for the removal of 
cortical tissue), and two with 2 mL of HypernateE (one for whole brain storage, the other 
for cortical tissue storage), as well as a dissection microscope for cortical dissection, and 
ice packs for brain removal, cortical dissection, and brain storage. 
 In order to dissect the embryonic cortical tissue, the pregnant mouse (16 days 
pregnant) was killed by cervical dislocation, then rinsed with ethanol to prevent 
contamination.  Her abdomen was cut open, and the uterus was removed.  Each 
embryonic pup was contained inside his/her own uterine sac within the uterus, but were 
linked together through a large placenta (Figure 6).  The uterus was rinsed with pouring 
medium and placed in the large dish for pup removal.  Once the uterus had been 
removed, each pup was removed from their sacs using a pair of forceps and scissors.  
These surgical steps remained constant throughout the project. 
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Once all the pups had been removed, the brains could be taken out.  Initially, the 
brain was removed by decapitating the pup and placing the head in a small culture dish 
with NB4 active medium.  The plate was then placed under the dissection microscope for 
dissecting: the head was anchored by placing a set of forceps through the eyes; another 
set of forceps was then used to separate the skull down the sagittal suture and to pull it 
open to each side revealing the brain; the brain was then removed with the forceps by 
scooping from underneath, severing any remaining membranous and spinal connective 
tissue, and placed in a separate culture dish for cortical dissection.  This procedure was 
modified to maximize the time efficiency and simplicity, and to increase the survival rate 
of the cortical cells.  The enhanced protocol did not require decapitation of the pups, 
instead, the pup was anchored by its neck with a pair of forceps, then similar to before, 
Figure 6: Diagram of the Mouse Uterus 
and Placenta for Removal of Pups 
(Nature Publishing Group, 2011). 
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another set of forceps was used to separate the skull down the sagittal suture, from here 
there was no need to pull the skull to the sides, instead the brain could easily be removed 
by gently squeezing slightly below the top of the brain with the forceps and slowly lifting 
it up and out, pinching underneath to sever any remaining membranous and spinal 
connective tissue.  The brain was then placed in a culture dish of HibernateE medium for 
cortical dissection.   These modifications are shown in Figures 7-9 (Nature Publishing 
Group, 2011).  Each step was preformed over ice to assist in preservation of the cortical 
cells. 
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After the brains were removed, another dissection was performed to remove the 
cortical tissue.  Due to the small size of the brain, and especially the cortex (Figures 10 – 
12) (Nature Publishing Group, 2011), this procedure was assisted through use of a 
dissection microscope.  The cortical tissue was accessed by placing the brain face up and 
using a pair of forceps to gently push from the sagittal suture out until the top layer 
unfolded, forming a crescent moon shape (Figure 11).  The outermost lighter arc of this 
shape is the cortex, which was removed using forceps, and placed in a separate small 
culture dish of HypernateE medium.  This procedure was then repeated for the opposite 
side of the brain.   
Eventually this procedure was changed to a more efficient means of removing the 
cortex, containing less non-cortical tissue contamination.  The improved method follows 
the same sequence of events with a slight alteration to the first step.  Before pushing open 
the top layer to reveal the cortex, the membrane enclosing the brain was removed; to do 
so the brain was placed upside down to easier view the membranous tissue (blood vessels 
used as guidelines) and forceps were used to gently unwrap the brain.  The procedure 
then continued as aforementioned.  The removal of this membrane allowed for more 
efficient separation of the cortical tissue into individual cells for non-clustered plating.  
These changes in the procedure led to a more efficient protocol, which allowed 
the cells to survive for up to two weeks, enabling lentiviral treatments.  Details of each of 
the procedures performed are shown in Appendices, A-D.  
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Plating Procedure  
 Prior to dissection, typically six to ten 6-well plates were prepared at least one day 
in advance: 1 mL of poly-L-lysine was pipetted into each well, then the plates were 
placed inside the 37°C incubator overnight.  After approximately 24 hours, the plates 
were removed from the incumbator and placed in the hood, then the poly-L-lysine was 
collected for reuse.  The wells were rinsed twice with sterile water, and left to dry in the 
sterile hood.  If plates were prepared in excess of one day prior to dissection, once dried 
they were labeled and stored in a plastic ziploc bag inside the 8°C refrigerator for later 
use.  Also prepared was the NB4 active plating medium containing 5% Δ FBS.  This 
medium was placed in the 37°C water bath during the dissection. 
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 After dissection, the removed cortices were taken off ice and placed in the sterile 
hood.  Using forceps, the cortical tissue was removed from the small culture dish and 
placed in a 1.5mL centrifuge tube containing protease solution to separate the cells.  In 
the beginning stages of the project, the cells were placed in trypsin, however later it was 
deterimined that papain (shown in Appendix B) was a more efficient protease for this 
process.  Upon addition of protease, the cells were then placed in a 37°C incubator for 
approximately 45 minutes, with agitation every five to ten minutes.  Post incubation, the 
cells were placed in the hood and slowly triturated ten times with a fire polished pipette.  
The cells were then observed under a microscope to ensure cell separation.  If still 
clustered, the cells were triturated an additional five times and allowed to settle.  Once 
settled, the cell suspension was collected and placed in a 15mL conical tube for a cell 
count.  
 In order to perform a cell count, 90 µL of trypan blue and 10 µL of the suspension 
was mixed in a single well of a microassay plate.  After thoroughly mixing, the solution 
was put in a hemocytometer and placed under the microscope.  The cells in each of the 
four primary quadrants were then individually counted, averaged and then mulitiplied by 
1 x 10
5
.  Using this number, the final volume containing 0.5 x 10
6
 cells/mL was 
calculated to dilute the remaining cell solution with the plating medium.  Upon dilution,  
2 mL of the appropriate solution was placed in each well.  The plates were then labeled 
with the cell type, date, and initials.  A final observation under the microscope was done 
to ensure they were single, nonclustered cells.   The plates were then placed in the 37°C 
incubator. 
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Cell Feeding 
 In preparation for media change, about 250 mL of feeding medium was made by 
adding antimitotics to the NB4 active media.  The basic proportions for 50 mL of 
medium were as follows:  0.484 µL/mL of 5‟UtP (24.2 µL/50mL NB4 active medium), 
0.2402 µL/mL of 5‟FdU (12.0 µL/50 mL NB4 active medium).  Prior to each media 
change, the feeding medium was placed in the 37°C water bath in order to prevent the 
growing cells from going into shock.   
 Initially, the first media change occured 24 hours after plating, and again every 
other day for approximately two weeks, cell viability permitting.  Due to significant cell 
death, it was determined that the cells were remaining in the plating medium for too long.  
As a result, the first media change was performed six hours after plating.  This was done 
by removing 1 mL of the medium to be replaced with 1 mL of fresh medium.  In the 
beginning of the project, this was done by aspiration, but was changed to pipetting for 
more accurate and gentle removal.  As mentioned above, this method was then repeated 
every 48 hours contigent on cell survival.   
  
 
 
Lentivirus Addition 
 
After approximately five days of cell growth, lentivirus was added to the cells  
with fresh medium and placed back in the incubator.  Twelve hours later, the medium 
was changed again; after this initial change the medium change resumed the 48 hour 
schedule with only one difference: for biosafety reasons the tips and medium were treated 
with bleach after use.  Initially, the lentivirus was added to the medium at a multiplicity 
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of infection (MOI) (number of viral particles per cell) of 0.5, but upon evaluation of the 
initial knockdown results, the MOI was increased to 1.0 and the tests are being repeated.  
High titer replication-deficient lentiviral stocks were prepared by Dr. Miguel Esteves, 
using a lentivirus based system that carries a GFP expression cassette with the shRNA in 
the 3‟UTR in the context of miR-30 sequences (shown previously in Figure 5).  To 
calculate the volume of lentivirus stock needed per well with a cell concentration of 1 x 
10
6
 cells/well, a simple calculation was performed using the following (a complete list of 
data found in Appendix E): 
(
                        
[     ]     
)
    
 
     
Gene 
GIPZ 
Clone 
Lenti 
Stock 
Titer 
(tu/mL) 
MOI 50 (Volume/well 
(µL)) 
Growth Medium 
Volume (µL) 
CCR10 
V2LMM
_12449 L647 7.55E+08 66.2 933.8 
 
After determining the volume of lentiviral stock needed for each well, all but 1 
mL of medium was removed from the wells, the lentivirus was added, and a calculated 
volume of feeding medium was added, bringing the final volume of the wells to 2 mL.  
The plates were then gently rocked to spread the lentivirus evenly over the cells, and 
returned to the 37°C incubator.  All pipettes and tips used in this process, and any used 
after transduction, were treated with bleach before disposal.  After three days, the GFP 
became visible in the cells, and after six days the cells were photographed and counted 
under the microscope (green versus clear) to calculate the percent transduced.  On the 
seventh day, the cells were harvested and prepared for quantitative real-time PCR by 
Wanzhao, an associate of Aronin‟s laboratory.  
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qRT-PCR 
 To test the knock down efficiency of the siRNAs, once the cells were harvested 
RNA was extracted and the expression of specific genes was assayed by quantitative real-
time PCR with SYBR green.  RNA was extracted and reverse transcribed to create 
cDNA.  This cDNA was then PCR-amplified through a series of 40 cycles, recording the 
fluorescence at the end of each as data for analysis.  The protocol followed was as per 
QIAGEN included with their qRT-PCR materials (QuantiTect® SYBR® Green PCR 
Handbook). 
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RESULTS 
 
 The goal of this project was to help develop a more efficient protocol for 
embryonic mouse cortical tissue dissection, plating, and maintenance, and to optimize 
their transduction with lentiviruses encoding siRNAs against candidate genes thought to 
encode proteins that interact with mHTT protein.   As described in Methods, the initial 
protocol for embryonic cortical tissue dissection, plating, and maintenance was 
significantly enhanced to eventually produce healthy primary neurons with a viable 
lifespan of about 2 weeks for further use in Dr. Aronin‟s investigations. Figures 13 and 
14 show healthy viable neurons.  Further evidence supporting the viability of these cells 
is the successful transduction of GFP-lentivirus into the cultured primary neurons (green 
fluorescing cells in Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Photomicrograph of Healthy Mouse Early Stage 
Primary Neurons. 
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Six days after transduction with 20 different siRNAs or scrambled siRNAs (and 
lentivirus not encoding any siRNA or GFP as negative controls), the number of 
fluorescing and clear cells per well were recorded (Figure 15).    
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Figure 8:  Number of Cells Transduced (Green) Versus Total Cell Count (Blue) for 
various siRNA Lentiviruses. 
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From this GFP data, the  percent of cells transduced was calculated (Figure 16).  
Although this data does not reflect siRNA efficiency, it helps show the transduction 
efficiency and reproducibility of the transduction protocol.  The data shows that the 
protocol is efficient, and it reproducibly tranduces the mouse primary neurons. 
 
 
Seven days after transduction, the cells were harvested and prepared for qRT-PCR 
with the goal of achieving at least 70% knockdown for each candidate mRNA.  RNA was 
extracted from each well and reverse transcribed to create cDNA.  The cDNA was then 
subjected to PCR to quantitate the cellular levels of specific candidate mRNAs.  Figure 
17 shows the mRNA knockdowns for the first trial at a viral MOI of 0.5.  Only 5 out of 
the 18 genes had ≥ 70% knockdown (ENPP5, STX1A, TRPC4, ROCK1 and ROCK 2).  
Figure 17 also shows the data collected thus far on the repeat experiments at MOI of 1.0.  
So far, 2 of the 5 tested mRNAs achieved the ≥ 70% knockdown target.  Using the 
greater MOI of virus, each gene showed at least a 9.7 increase in the percent knockdown. 
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Gene CACNA1D showed the largest increase of an additional 25.4% knockdown.  Out of 
the two genes that had ≥ 70% knock down at MOI 1.0 (ENPP5 and GPD1), one had not 
already met this qualification at MOI 0.5 (GPD1).  This data shows that the protocols 
optimized in this project efficiently transduce mouse cortical neurons to silence several 
selected genes of choice. 
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DISCUSSION 
 
 
 This project used previous advances related to the siRNA silencing of specific 
genes to establish protocols for applying their use to Huntington‟s disease, especially to 
investigate candidate genes previously thought to encode proteins that interact with 
mHTT protein.  Since it has been established that mouse and human genomes contain 
many similar genes, the findings in mice may eventually apply to human HD patients. 
A few problems were encountered throughout the project.  Most were minor and 
easily resolved; others were more difficult and called for specialized attention.  One of 
the initial problems encountered was the mice were not getting pregnant; this was 
speculated to be due to issues with the light timers and sounds from the construction 
blasts interrupting the mice‟s internal clocks and mating habits.  As a result, the pace of 
the project varied, and it was difficult to progress.  This was eventually resolved by 
ordering the pregnant mice and having them delivered to UMass directly, ensuring 
pregnancy.  Another issue was lack of neuronal cell growth.  Upon further investigation, 
it was found that the major issue was that the cells were being over triturated, causing 
them to die prior to plating.  Although this was easy to fix, there was another situation in 
which the cells became contaminated, which impeded progression for approximately two 
weeks.  This required outside assistance to ensure that the incubator was sterile and 
working properly.  Despite these issues, the project progressed at a relatively smooth and 
consistent pace.  
  The data collected throughout this project showed that the enhanced protocol for 
mouse cortical dissection and plating enabled cultured primary neurons to sustain a 
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healthy viable lifespan for about 2 weeks, which should facilitate the lab‟s ongoing HD 
research.  Using the lentiviral protocol, several different siRNA‟s were successfully 
transduced into the cultured primary neurons.  qRT-PCR showed how efficiently the 
siRNAs were able to knock down the mRNAs; the goal was to achieve ≥ 70% 
knockdown.  Upon evaluation of the initial results at viral MOI of 0.5, the virus was 
increased to MOI 1.0 to attain at least 70% knockdown for each protein, and the 
experiments were repeated (at this point only a few genes have been analyzed at the 
increased MOI).  Most labs consider 50 – 90% acceptable for successful knockdown.  
The MOI can be increased to 2.0 if needed in the future. 
In continuation, these siRNAs (shRNA genes encoding them) will be inserted into 
Adeno-associated viruses (AAV) which will be unilaterally injected into mouse striatum 
to assess the role of these proteins in HD pathogenesis.  These injections will contain 
either scAAV9-shRNAmir, or control vectors, injected into HD and WT four month old 
littermates.  Eighty days post-injection, the brains will be collected for qRT-PCR analysis 
of the knockdown efficiency, as well as the histological and biochemical status of the 
disease.  By analyzing this data, it is expected that the roles of these proteins will be 
better understood in correlation to HD pathogenicity.  If successful, Dr. Aronin‟s lab will 
continue to add to the foundations of our knowledge of HD, allowing researchers to 
refine their investigations to focus on the beginning stages of HD to help find a cure.  
 If the knockdown of the genes is confirmed in vivo, accompanied by a decrease in 
the pathophysiology of the disease, a group of WT and mHTT mice can be re-injected 
with that specific AAV siRNA and observed.  These observations, in correlation with 
task and behavioral assays, as well as neuroimaging, will allow researchers to compare 
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the progression of Huntington‟s disease between non-afflicted mice, afflicted non-treated 
mice, and siRNA treated afflicted mice.  In doing so, they will be able to accurately 
define the effects of each protein on the disease, and gauge whether the siRNA can be 
used for human therapy.  If siRNA therapy works in humans, this could provide a major 
breakthrough for treating this debilitating this disease, extending the lifespan of millions 
of people affected by Huntington‟s disease.   
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Appendix C 
 
Dissection Protocol: Cortical Cells – version one  
Prior to Dissection Day 
 Coat 6 well plates with Poly-L-Lysine  
o Place 1mL of Poly-L-Lysine in each well and leave in incubator overnight  
o Aspirate coating and rinse with 1mL of water twice 
o Label and date plates, store in plastic bag in refrigerator  
 Sterilize instruments to be used during dissection 
 
Dissection Day 
 
Turn on sterilizer to heat 
 
  Prepare for Dissection and Plating: 
 Remove coated plates from refrigerator and place in hood to warm 
 Prepare  NB4 active with 5% ΔFBS and place in warm water bath (2.5mL in 50 
mL) 
 Remove Trypson from refrigerator and place in hood 
 Place 1.5mL centrifuge tubes in hood 
 
  On Lab Bench: 
 Prepare lab bench: two draped areas  
o Removal of fetal mice: forceps and scissors, one beaker with about 300 
mL of 70% ethanol, one beaker with about 50mL of pouring media 
(DMEM-F12), one large cell culture plate with 5mL of cold DMEM-F12 
for uterus  
o Brain dissection: forceps and scissors, one large cell culture plate with 
5mL cold DMEM-F12 for heads, three small cell culture plates with 2mL 
of cold HybernateE for brains and cortex, microscope, ice to place brains 
on 
 Kill mouse and immediately dip in 70% ethanol 
 Place on drape and cut through skin and muscle layers using a pair of sterile 
scissors and forceps 
 Remove uterus by holding one end with a new pair of sterile forceps and snipping 
with a new pair of sterile scissors 
 Pour DMEM-F12 over uterus and place in large cell culture plate 
 Move to other drape, cut uterus open with a new pair of sterile scissors to remove 
pups 
 Snip head off the pups and place in second large cell culture plate and put on ice 
 Using sterile forceps and a microscope, remove brain from each head and place 
in small plate on ice  
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 Use forceps to open the brain and remove cortical tissue and place in second 
small plate on ice 
 
In Hood: 
 Using forceps place all cortical tissue pieces from small cell culture plate in15mL 
conical tube containing 1ml Triple E Express (trypsin) 
 Place tissue/enzyme into 37ºC incubator for 20-30 minutes 
 After 30 minute digestion remove the supernatant and re-suspend pieces in 1mL 
of warm 5%ΔFBS inNB4 active media 
 Allow tissue to settle and remove most of the media and replace with new media 
 Transfer re-suspended cells to 15mL conical tube (or triturate in the small tube if 
desired) 
 Triturate 15-20 times slowly using a wet glass fire-polished pipette 
 Allow 2 minutes for large pieces to settle out and put supernatant into a new 15ml 
conical tube. If there are many pups, use a 50 ml conical tube. 
 Mix 90ul of trypan blue with 10ul of cells using a sterile pipette tip. Place 10ul in 
hemocytometer and count four quadrants.  Average the four numbers and multiply 
by 1.0x10⁵.  Calculate volume needed to get 0.5 x 10⁶ cells/mL. 
 Make dilution using 5%FBS in NB4 active media 
 Plate diluted cells by adding 2mL into each well of the coated 6 well plates 
 Check cells using microscope to be sure they are single cells 
 Place in 37ºC incubator 
 Make feeding media (NB4 active + antimitotics) for days to come: 
o Calculate media based on number of plated wells (2mL/well): 
6 ml per plate every other day for 14 days = 42 mL, so make 50 mL for each 6 
well plate 
     0.484µL/mL of 5‟UtP (24.2µL / 50 mL NB4 active) 
     0.2402 µL/mL of 5‟FdU (12.0µL / 50 mL NB4 active) 
 
Feeding  
 After 6 -12 hours: change media by removing 1mL of media using a pipette 
(making sure not to disturb cells) and adding 1mL of feeding media  
 Store in 37ºC incubator and repeat every 48 hours   
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Appendix D 
 
Dissection Protocol: Cortical Cells – version two  
Prior to Dissection Day 
 Coat 6 well plates with Poly-L-Lysine  
o Place 1mL of Poly-L-Lysine in each well and leave in incubator overnight  
o Aspirate coating and rinse with 1mL of water twice 
o Label and date plates, store in plastic bag in refrigerator  
 Sterilize instruments to be used during dissection 
 
Dissection Day 
 
Turn on sterilizer to heat 
 
  Prepare for Dissection and Plating: 
 Remove coated plates from refrigerator and place in hood to warm 
 Prepare  NB4 active with 5% ΔFBS and place in warm water bath (2.5mL in 50 
mL) 
 Prepare the papain solutions and place in hood 
 Place 1.5mL centrifuge tubes in hood 
 
  On Lab Bench: 
 Prepare lab bench: two draped areas  
o Removal of fetal mice: forceps and scissors, one beaker with about 300 
mL of 70% ethanol, one beaker with about 50mL of pouring media 
(DMEM-F12), one large cell culture plate with 5mL of cold DMEM-F12 
for uterus  
o Brain dissection: forceps and scissors, one large cell culture plate with 
5mL cold DMEM-F12 for heads, three small cell culture plates with 2mL 
of cold HybernateE for brains and cortex, microscope, ice to place brains 
on 
 Kill mouse and immediately dip in 70% ethanol 
 Place on drape and cut through skin and muscle layers using a pair of sterile 
scissors and forceps 
 Remove uterus by holding one end with a new pair of sterile forceps and snipping 
with a new pair of sterile scissors 
 Pour DMEM-F12 over uterus and place in large cell culture plate 
 Move to other drape, cut uterus open with a new pair of sterile scissors to remove 
pups 
 Anchor pups using a forcep and clasping the neck, using a second forcep make an 
incision down the sagittal suture line 
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 Gently squeeze from just beneath the brain while pushing up; separate the brain 
from the body by pinching the membranous and connective tissue and scooping 
the brain from beneath  
 Place each brain in the small dish of HypenateE on ice  
 Use forceps to open the brain and remove cortical tissue and place in second 
small plate on ice 
 
In Hood: 
 Using forceps place all cortical tissue pieces from small cell culture plate in1.5mL 
centrifuge tube containing Papain solution 
 Place tissue/enzyme into 37ºC incubator for 40-50 minutes, mixing every 10 
minutes 
 After 40 - 50 minute digestion remove the supernatant and re-suspend pieces in 
1mL of warm 5%ΔFBS inNB4 active media 
 Allow tissue to settle and remove most of the media and replace with new media 
 Transfer re-suspended cells to 15mL conical tube (or triturate in the small tube if 
desired) 
 Triturate 10 times slowly using a wet glass fire-polished pipette 
 Allow 2 minutes for large pieces to settle out and put supernatant into a new 15ml 
conical tube. If there are many pups, use a 50 ml conical tube. 
 Mix 90ul of trypan blue with 10ul of cells using a sterile pipette tip. Place 10ul in 
hemocytometer and count four quadrants.  Average the four numbers and multiply 
by 1.0x10⁵.  Calculate volume needed to get 0.5x 10⁶ cells/mL. 
 Make dilution using 5%FBS in NB4 active media 
 Plate diluted cells by adding 2mL into each well of the coated 6 well plates 
 Check cells using microscope to be sure they are single cells 
 Place in 37ºC incubator 
 Make feeding media (NB4 active + antimitotics) for days to come: 
o Calculate media based on number of plated wells (2mL/well): 
6 ml per plate every other day for 14 days = 42 mL, so make 50 mL for each 6 
well plate 
     0.484µL/mL of 5‟UtP (24.2µL / 50 mL NB4 active) 
     0.2402 µL/mL of 5‟FdU (12.0µL / 50 mL NB4 active) 
 
Feeding  
 After 6 -12 hours: change media by removing 1mL of media using a pipette 
(making sure not to disturb cells) and adding 1mL of feeding media  
 Store in 37ºC incubator and repeat every 48 hours   
Appendix E 
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Gene GIPZ Clone 
Lenti 
Stock 
Titer 
(tu/mL) 
MOI 
50:100 
(Volume 
per well in 
µL) 
Growth 
Medium 
Volume 
(µL) 
CCR10 V2LMM_12449 L647 7.55E+08 66.2 933.8 
Scrambled - L648 2.18E+09 22.9 977.1 
Empty - L649 4.23E+08 118.2 881.8 
DAPK2 v2LMM_188057 L650 2.71E+09 18.5 981.5 
ENPP5 v2LMM_30736 L651 5.33E+08 93.8 906.2 
CTNNB1 V2LMM _16708  L653 5.92E+09 8.4 991.6 
STX1A V3LMM_415458 L654 9.44E+09 5.3 994.7 
CACNA1D V2LHS_112214 L655 3.53E+09 14.2 985.8 
GPD1 V3LHS _640972 L656 6.51E+09 7.7 992.3 
VDAC2 v2lmm20438 l665 4.20E+08 119.0 881.0 
ROCK1  v3lhs_338550 L666 2.60E+09 19.2 980.8 
ROCK 2 v2lmm_10488 L667 3.20E+09 15.6 984.4 
empty N/A L668 2.50E+08 200.0 800.0 
MAP3K11 V3LMM_501715 L673 2.17E+10 2.3 997.7 
USP9X V3LMM_477651 L674 4.15E+09 12.0 988.0 
RAB11A V2LMM_48972 L675 2.05E+09 24.4 975.6 
Scrambled - L648 2.18E+09 22.9 977.1 
MAP3K11 V3LMM_501715 L673 2.17E+10 2.3 997.7 
USP9X V3LMM_477651 L674 4.15E+09 12.0 988.0 
RAB11A V2LMM_48972 L675 2.05E+09 24.4 975.6 
VDAC2 v2lmm20438 L686 1.70E+09 29.4 970.6 
CACNA2D1 V2LMM_75500 L688 7.30E+09 6.8 993.2 
TRPC4 V2LMM_62022 L689 7.30E+09 6.8 993.2 
ENPP5 v2LMM_30736 L695 6.80E+09 7.4 992.6 
